Aché is among the most important Brazilian pharmaceutical groups. Company has 100% national capital. It is 49 years of history and leadership in the local industry.
Supported by a team of about 4.500 employees, Aché manufactures and promotes 303 drugs, in 747 different versions, among RX, OTC and generic products. The excellence of a sales force of over 2.500 medical representatives – which is considered the best in the Brazilian market has allowed Aché to maintain its first position in prescription generation, confirming itself as the favorite laboratory for Brazilian physicians.
Investing in portfolio renewal is an essential part of the sustainable growth strategy devised by Aché over the last years. To reach the high number of launches in 2013 – 32 in the year – and keep the growth perspectives for the future, the Company allocated in the period R$ 54.9 million to research and development. Results for 2014 and the next years will be incremented by the 184 projects in the company’s pipeline.
Licensing agreements allow consolidating Aché’s brands in countries in the Americas, Asia and Africa, composing a portfolio of over 40 pharmaceutical formulations.